NASDAQ:AQST Aquestive Therapeutics (AQST) Stock Price, News & Analysis $4.18 -0.05 (-1.18%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$4.10▼$4.2750-Day Range$2.40▼$4.6552-Week Range$1.25▼$6.23Volume625,674 shsAverage Volume1.84 million shsMarket Capitalization$380.54 millionP/E RatioN/ADividend YieldN/APrice Target$7.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Aquestive Therapeutics alerts: Email Address Aquestive Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.14 Rating ScoreUpside/Downside87.4% Upside$7.83 Price TargetShort InterestBearish11.85% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.47) to ($0.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.63 out of 5 starsMedical Sector835th out of 910 stocksPharmaceutical Preparations Industry388th out of 426 stocks 3.6 Analyst's Opinion Consensus RatingAquestive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAquestive Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Aquestive Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.85% of the outstanding shares of Aquestive Therapeutics have been sold short.Short Interest Ratio / Days to CoverAquestive Therapeutics has a short interest ratio ("days to cover") of 7.1.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldAquestive Therapeutics does not currently pay a dividend.Dividend GrowthAquestive Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AQST. Previous Next 1.6 News and Social Media Coverage News SentimentAquestive Therapeutics has a news sentiment score of -0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.Search Interest15 people have searched for AQST on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Aquestive Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aquestive Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.85% of the stock of Aquestive Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 32.45% of the stock of Aquestive Therapeutics is held by institutions.Read more about Aquestive Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aquestive Therapeutics are expected to decrease in the coming year, from ($0.47) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aquestive Therapeutics is -9.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aquestive Therapeutics is -9.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Aquestive Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> About Aquestive Therapeutics Stock (NASDAQ:AQST)Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Read More AQST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AQST Stock News HeadlinesAugust 22, 2024 | globenewswire.comAquestive Therapeutics to Participate in Two Upcoming Investor ConferencesAugust 16, 2024 | finance.yahoo.comAQST Sep 2024 0.500 call (AQST240920C00000500)September 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 12, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Aquestive Therapeutics (AQST)August 10, 2024 | markets.businessinsider.comAquestive Therapeutics: Strong Buy Recommendation on Revenue Performance and Pipeline ProgressAugust 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Aquestive Therapeutics Amid Promising Anaphylm™ Trials and Anticipated LaunchAugust 8, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Aquestive Therapeutics (AQST)August 8, 2024 | msn.comAquestive Therapeutics GAAP EPS of -$0.03 beats by $0.09, revenue of $20.09M beats by $7.71MSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 7, 2024 | markets.businessinsider.comAquestive Therapeutics: Strong Buy on Robust PharmFilm Progress and Solid FinancialsAugust 7, 2024 | seekingalpha.comAquestive Therapeutics Inc. (AQST) Q2 2024 Earnings Call TranscriptAugust 6, 2024 | markets.businessinsider.comAquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 6, 2024 | globenewswire.comAquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateJuly 30, 2024 | finance.yahoo.comInstitutions profited after Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) market cap rose US$72m last week but retail investors profited the mostJuly 26, 2024 | seekingalpha.comAQST Aquestive Therapeutics, Inc.July 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Aquestive Therapeutics Amid Anaphylm’s Promising Developments and Market PotentialJuly 25, 2024 | globenewswire.comAquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration StudyJuly 23, 2024 | globenewswire.comAquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ETSee More Headlines Receive AQST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AQST CUSIPN/A CIK1398733 Webwww.aquestive.com Phone(908) 941-1900FaxN/AEmployees160Year FoundedN/APrice Target and Rating Average Stock Price Target$7.83 High Stock Price Target$10.00 Low Stock Price Target$4.00 Potential Upside/Downside+87.4%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,870,000.00 Net Margins-44.07% Pretax Margin-44.14% Return on EquityN/A Return on Assets-28.26% Debt Debt-to-Equity RatioN/A Current Ratio7.49 Quick Ratio6.98 Sales & Book Value Annual Sales$58.36 million Price / Sales6.52 Cash FlowN/A Price / Cash FlowN/A Book Value($0.39) per share Price / Book-10.72Miscellaneous Outstanding Shares91,039,000Free Float83,892,000Market Cap$380.54 million OptionableOptionable Beta2.84 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Daniel Barber (Age 48)CEO, President & Director Comp: $1.06MMr. A. Ernest Toth Jr. (Age 65)Chief Financial Officer Comp: $667.19kMs. Lori J. Braender BSBA (Age 68)Esq., J.D., Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $713.22kMs. Cassie Jung (Age 44)Senior Vice President of Operations Mr. Alexander Mark Schobel (Age 65)Chief Innovation & Technology Officer Comp: $672.69kDr. Stephen Wargacki (Age 45)Chief Science Officer Mr. Peter E. Boyd (Age 58)Senior Vice President of IT, HR & Communications Dr. Gary H. Slatko M.D. (Age 66)MBA, Chief Medical Officer Dr. Carl N. Kraus M.D. (Age 54)Chief Medical Officer Mr. Robert Charles ArnoldVP of Finance, Controller & Assistant SecretaryMore ExecutivesKey CompetitorsXeris BiopharmaNASDAQ:XERSChiasmaNASDAQ:CHMAOptiNoseNASDAQ:OPTNChimerixNASDAQ:CMRXFortress BiotechNASDAQ:FBIOView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 63,270 shares on 9/5/2024Ownership: 0.069%Blue Owl Capital Holdings LPBought 265,000 shares on 8/15/2024Ownership: 1.252%Deerfield Management Company L.P. Series CBought 146,155 shares on 8/15/2024Ownership: 0.161%The Manufacturers Life Insurance Company Bought 29,371 shares on 8/15/2024Ownership: 0.032%Marshall Wace LLPBought 77,016 shares on 8/14/2024Ownership: 0.085%View All Insider TransactionsView All Institutional Transactions AQST Stock Analysis - Frequently Asked Questions How have AQST shares performed this year? Aquestive Therapeutics' stock was trading at $2.02 at the start of the year. Since then, AQST shares have increased by 106.9% and is now trading at $4.18. View the best growth stocks for 2024 here. How were Aquestive Therapeutics' earnings last quarter? Aquestive Therapeutics, Inc. (NASDAQ:AQST) posted its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.08. The company had revenue of $20.10 million for the quarter, compared to analysts' expectations of $12.62 million. When did Aquestive Therapeutics IPO? Aquestive Therapeutics (AQST) raised $60 million in an initial public offering (IPO) on Wednesday, July 25th 2018. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers. Who are Aquestive Therapeutics' major shareholders? Top institutional shareholders of Aquestive Therapeutics include Blue Owl Capital Holdings LP (1.25%), Renaissance Technologies LLC (0.55%), Legato Capital Management LLC (0.27%) and Bank of New York Mellon Corp (0.25%). Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, Peter E Boyd and Lori J Braender. View institutional ownership trends. How do I buy shares of Aquestive Therapeutics? Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aquestive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO) and Organigram (OGI). This page (NASDAQ:AQST) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquestive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AQST Stock Alerts